| アブストラクト | BACKGROUND: Olanzapine is an atypical antipsychotic used to treat schizophrenia and manic episodes. Its potential thromboembolic risk has been reported, but the evidence remains controversial. This study aimed to comprehensively evaluate the association between olanzapine and pulmonary embolism (PE) and venous thromboembolism (VTE). METHODS: This study combined meta-analysis and signal mining from the FDA Adverse Event Reporting System (FAERS) database to assess the association between olanzapine and pulmonary embolism (PE) and venous thromboembolism (VTE). RESULTS: From 55,905 olanzapine-related adverse event reports in the Faers database, 1,233 significant signals were identified, including serious adverse events not fully documented on the drug label, such as pulmonary embolism and venous embolism. A meta-analysis of eight studies showed that olanzapine use significantly increased the risk of VTE and pulmonary embolism (OR = 2.07, 95% CI: 1.37-3.14, P = 0.0006). CONCLUSION: These findings suggest that olanzapine is associated with an increased risk of thromboembolic events; therefore, enhanced clinical surveillance and further investigation into its safety are necessary. SYSTEMATIC REVIEW REGISTRATION: https://www.crd.york.ac.uk/prospero/, identifier CRD420251003254. |
|---|
| ジャーナル名 | Frontiers in cardiovascular medicine |
|---|
| Pubmed追加日 | 2026/2/27 |
|---|
| 投稿者 | Zhang, XueSong; Sun, SiMan; Fan, XiaoYu; Guo, ShuShu; Li, WanFang; Wang, Chuan; Xu, Jia; Chen, ChongZe; Jin, HongTao |
|---|
| 組織名 | School of Pharmacy, Shaanxi University of Chinese Medicine, Xianyang, China.;New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy;of Medical Sciences & Peking Union Medical College, Beijing, China.;College of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical;University, Shenyang, China.;Beijing Union-Genius Pharmaceutical Technology Development Co., Ltd., Beijing,;China.;Department of Dermatology, Beijing Hospital of Traditional Chinese Medicine,;Capital Medical University, Beijing, China.;Department of Pharmacy, Fuzhou Changle People's District Hospital, Fuzhou, China.;Beijing Key Laboratory of Key Technologies for Preclinical Research and;Development of Innovative Drugs in Pharmacokinetics and Pharmacodynamics,;Beijing, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41756513/ |
|---|
